Eva Dombi

7.6k total citations
98 papers, 3.3k citations indexed

About

Eva Dombi is a scholar working on Neurology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eva Dombi has authored 98 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Neurology, 39 papers in Epidemiology and 26 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eva Dombi's work include Neurofibromatosis and Schwannoma Cases (83 papers), Meningioma and schwannoma management (35 papers) and Neuroblastoma Research and Treatments (33 papers). Eva Dombi is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (83 papers), Meningioma and schwannoma management (35 papers) and Neuroblastoma Research and Treatments (33 papers). Eva Dombi collaborates with scholars based in United States, Germany and Canada. Eva Dombi's co-authors include Brigitte C. Widemann, Seth M. Steinberg, Pamela L. Wolters, Elizabeth Fox, Frank M. Balis, Andrea Gillespie, Nancy Ratner, Jianqiang Wu, Andrea Baldwin and Mi‐Ok Kim and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Eva Dombi

94 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Dombi United States	35	2.5k	1.1k	975	498	470	98	3.3k
Victor F. Mautner Germany	27	2.0k 0.8×	891 0.8×	556 0.6×	678 1.4×	329 0.7×	68	2.4k
Donald C. Wright United States	31	1.3k 0.5×	1.4k 1.3×	854 0.9×	900 1.8×	223 0.5×	62	3.4k
Jane Chatten United States	29	1.7k 0.7×	578 0.5×	740 0.8×	327 0.7×	1.1k 2.3×	71	3.0k
Martin J. Rutkowski United States	30	1.2k 0.5×	1.5k 1.4×	409 0.4×	357 0.7×	324 0.7×	84	3.2k
Kwan Park South Korea	30	1.5k 0.6×	890 0.8×	419 0.4×	86 0.2×	221 0.5×	126	2.8k
Jean‐Michel Zucker France	32	971 0.4×	351 0.3×	1.5k 1.5×	359 0.7×	813 1.7×	77	3.7k
Renato Scienza Italy	29	1.2k 0.5×	612 0.6×	452 0.5×	127 0.3×	509 1.1×	96	2.9k
Yoko Nakasu Japan	30	705 0.3×	637 0.6×	723 0.7×	175 0.4×	448 1.0×	145	2.7k
David W. Kimmel United States	31	1.3k 0.5×	539 0.5×	873 0.9×	210 0.4×	1.2k 2.5×	50	3.8k
Judith A. Murovic United States	30	824 0.3×	573 0.5×	407 0.4×	195 0.4×	268 0.6×	63	2.9k

Countries citing papers authored by Eva Dombi

Since Specialization

Citations

This map shows the geographic impact of Eva Dombi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Dombi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Dombi more than expected).

Fields of papers citing papers by Eva Dombi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Dombi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Dombi. The network helps show where Eva Dombi may publish in the future.

Co-authorship network of co-authors of Eva Dombi

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Dombi. A scholar is included among the top collaborators of Eva Dombi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Dombi. Eva Dombi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Adeyemi, Ayoade, Andrea M. Gross, Andrea Baldwin, et al.. (2025). Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm. Neuro-Oncology Advances. 7(1). vdaf101–vdaf101.

Ahmari, Niousha, Kwangmin Choi, Jianqiang Wu, et al.. (2025). Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas. Life Science Alliance. 8(12). e202503359–e202503359.

Gross, Andrea M., Lauren Baldwin, Ashley Cannon, et al.. (2025). Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib. JAMA Dermatology. 161(5). 533–533. 1 indexed citations

Gross, Andrea M., Sana Mahmood, Eva Dombi, et al.. (2024). Challenges in determining the malignant potential of atypical neurofibromas (aNF) using histopathologic features and the potential need for CDKN2A/2B testing: a case report. 8(2). 207–15. 1 indexed citations

Ahmari, Niousha, Jay Pundavela, Sara Szabo, et al.. (2024). C5aR plus MEK inhibition durably targets the tumor milieu and reveals tumor cell phagocytosis. Life Science Alliance. 7(5). e202302229–e202302229. 4 indexed citations

Lemberg, Kathryn M., Andrea M. Gross, David J. Liewehr, et al.. (2024). Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment. Pediatric Research. 97(6). 1918–1928. 1 indexed citations

Gross, Andrea M., Eva Dombi, Pamela L. Wolters, et al.. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 25(10). 1883–1894. 44 indexed citations

Kotch, Chelsea, Eva Dombi, Amish C. Shah, et al.. (2023). Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1. The Journal of Pediatrics. 260. 113513–113513. 2 indexed citations

Jackson, Mark, Niousha Ahmari, Jianqiang Wu, et al.. (2023). Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. Journal of Pharmacology and Experimental Therapeutics. 385(2). 106–116. 8 indexed citations

10.

Glod, John, Miki Kasai, Joanne Derdak, et al.. (2020). Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas. Clinical Cancer Research. 26(23). 6112–6121. 21 indexed citations

11.

Choi, Kwangmin, Liang Hu, Robert F. Hennigan, et al.. (2020). MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK. Oncogene. 40(5). 951–963. 18 indexed citations

12.

Patel, Ami V., Jianqiang Wu, Kwangmin Choi, et al.. (2020). Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST. Cancer Research. 80(21). 4720–4730. 26 indexed citations

13.

Ma, Yun, Andrea M. Gross, Eva Dombi, et al.. (2020). A molecular basis for neurofibroma-associated skeletal manifestations in NF1. Genetics in Medicine. 22(11). 1786–1793. 16 indexed citations

14.

Pemov, Alexander, Nancy F. Hansen, Sivasish Sindiri, et al.. (2019). Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas. Neuro-Oncology. 21(8). 981–992. 69 indexed citations

15.

Kraft, Ira L., Srivandana Akshintala, Haiyan Lei, et al.. (2017). Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research. 24(4). 753–765. 20 indexed citations

16.

Blakeley, Jaishri O., Xiaobu Ye, Dan G. Duda, et al.. (2016). Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas. Journal of Clinical Oncology. 34(14). 1669–1675. 86 indexed citations

17.

Wolters, Pamela L., Staci Martin, Andrea Baldwin, et al.. (2015). Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social‐emotional functioning, and quality of life. American Journal of Medical Genetics Part A. 167(9). 2103–2113. 75 indexed citations

18.

Fox, Elizabeth, Brigitte C. Widemann, Meredith K. Chuk, et al.. (2013). Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Clinical Cancer Research. 19(15). 4239–4248. 110 indexed citations

19.

Lodish, Maya, Ninet Sinaii, Ethan Bornstein, et al.. (2012). Bone mineral density in children and young adults with neurofibromatosis type 1. Endocrine Related Cancer. 19(6). 817–825. 20 indexed citations

20.

Dombi, Eva, et al.. (2008). Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro-Oncology. 10(4). 593–598. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact